adebrelimab
Small moleculeexperimental
Clinical trial activity
223 trials · 48 clinical orgs · 0 marketing orgs
Phase 1
56
Phase 2
191
Phase 3
17
Phase 4
1
Earliest trial started Jun 26, 2017 (NCT03133247)
Timeline
Indications
Studied for
- Bevacizumab · Phase 2
- Biliary Tract Neoplasms · Phase 3
- Biomarkers · Phase 2
- Breast Neoplasms · Phase 2
- Bronchial Neoplasms · Phase 2
- Carcinoma, Bronchogenic · Phase 2
- Carcinoma, Hepatocellular · Phase 3
- Carcinoma, Non-Small-Cell Lung · Phase 3
- Carcinoma, Squamous Cell · Phase 2
- Carcinoma, Transitional Cell · Phase 2
- Cholangiocarcinoma · Phase 2
- Colorectal Neoplasms · Phase 2
- Decitabine · Phase 1/Phase 2
- Drug-Related Side Effects and Adverse Reactions · Phase 2
- Drugs, Investigational · Phase 2
- Drug Therapy · Phase 2
- Esophageal Neoplasms · Phase 2/Phase 3
- Esophageal Squamous Cell Carcinoma · Phase 2
- Gastrointestinal Neoplasms · Phase 2
- Immunotherapy · Phase 2
- Lapatinib · Phase 2
- Liver Neoplasms · Phase 2
- Lung Diseases · Phase 2
- Lung Neoplasms · Phase 2
- Lymphoma · Phase 1
- Nasopharyngeal Carcinoma · Phase 3
- Nasopharyngeal Neoplasms · Phase 2
- Neoadjuvant Therapy · Phase 3
- Neoplasm Metastasis · Phase 1
- Neoplasms · Phase 2
- Neoplasms by Site · Phase 2
- Neuroendocrine Tumors · Phase 2
- Osteosarcoma · Phase 1
- Ovarian Diseases · Phase 2
- Ovarian Neoplasms · Phase 2/Phase 3
- Pancreatic Neoplasms · Phase 2
- Perioperative Period · Phase 2
- Prostatic Neoplasms, Castration-Resistant · Phase 2
- Radiosurgery · Phase 2
- Radiotherapy · Phase 2
- Rectal Neoplasms · Phase 2
- Respiratory Tract Diseases · Phase 2
- Respiratory Tract Neoplasms · Phase 2
- Sarcoma · Phase 1
- Small Cell Lung Carcinoma · Phase 3
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Stomach Neoplasms · Phase 4
- Thoracic Neoplasms · Phase 2
- Thyroid Neoplasms · Phase 2
- Triple Negative Breast Neoplasms · Phase 2
- Urinary Bladder Neoplasms · Phase 2
- Uterine Cervical Neoplasms · Phase 3
Mechanism of action
- Programmed cell death 1 ligand 1INHIBITOR
CD274 inhibitor
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297828 ↗
Also known as
- shr-1316
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07266025 | Phase 2 | Jan 30, 2026 | Fudan University |
| NCT07296341 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2025 | Hengrui Therapeutics, Inc. |
| NCT07281209 | Phase 2 | Dec 31, 2025 | Jiao Tong University |
| NCT07268040 | Phase 2 | Dec 31, 2025 | Hengrui Therapeutics, Inc. |
| NCT07239596 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2025 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT07238569 | Phase 3 | Dec 1, 2025 | Sun Yat-Sen University |
| NCT07229586 | Phase 1/Phase 2 (Phase 2) | Nov 30, 2025 | Hengrui Therapeutics, Inc. |
| NCT07229729 | Phase 2 | Nov 30, 2025 | Hengrui Therapeutics, Inc. |
| NCT07230301 | Phase 2 | Nov 30, 2025 | Jinlin University |
| NCT07229625 | Phase 3 | Nov 30, 2025 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT07241793 | Phase 2 | Nov 20, 2025 | Guangzhou Medical University, Huazhong University of Science and Technology, Kunming Medical University, Sun Yat-Sen University |
| NCT07241767 | Phase 2 | Nov 12, 2025 | Hengrui Therapeutics, Inc. |
| NCT07168200 | Phase 3 | Oct 17, 2025 | Government of China |
| NCT07111832 | Phase 3 | Sep 30, 2025 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT07192848 | Phase 2 | Sep 30, 2025 | Chinese Academy of Medical Sciences |
| NCT07200154 | Phase 2 | Sep 30, 2025 | Peking University |
| NCT07284992 | Phase 2 | Sep 12, 2025 | Shandong Provincial Hospital |
| NCT07069270 | Phase 2 | Sep 1, 2025 | Fujian Medical University |
| NCT07131514 | Phase 2 | Aug 31, 2025 | Hengrui Therapeutics, Inc., Jiao Tong University |
| NCT07141264 | Phase 2 | Aug 25, 2025 | People's Liberation Army of China |
Showing 20 of 223 trials
Page 1 / 12
Organizations
Research & Development (48)
48 organizations
Page 1 / 3